Treatment
Customisation
Due to the precision and flexibility of Sonablate HIFU, patients and physicians
can decide on a customised treatment plan tailored to their prostate cancer diagnosis.
Standard
HIFU Procedure
The standard HIFU procedure with the Sonablate ablates the entire prostate gland.
This procedure is the most appropriate choice of HIFU treatment
for patients who have organ confined prostate cancer which
is not limited to one discrete area of the prostate.
The benefits of a standard HIFU procedure:
- 92% of patients are successfully
treated1
- Over 99% of men remain continent1
- 70% of men retain erectile function1
- Usually a day case
- Non surgical
- No radiation
- The procedure can be repeated as
necessary, and does not rule out other treatment options
Focal
HIFU
Focal HIFU is an emerging technique for the treatment of prostate cancer where
only the tumour is treated instead of the whole prostate gland. By avoiding
important structures located around the prostate side-effects could be reduced.
It may be suitable for men with low or intermediate risk cancer, who have a
single tumour inside the prostate or several tumours all on the same side of
the gland.
Benefits of a focal HIFU procedure:
- Nearly 100% continence2
- Nearly 100% erectile function2
- Short procedure time (20-90 minutes)
- Non surgical
- No radiation
- Rapid return to normal life after
treatment
- The procedure can be repeated as
necessary, and does not rule out other treatment options
A clinician can determine if a patient
is a candidate for the standard or focal Sonablate HIFU procedure.
All medical procedures have risks and
benefits; all potential side effects and complications should
be discussed with a physician prior to undergoing any procedure.
Please see the potential side effects section of the website
for a complete list of possible complications from the HIFU
procedure.
1 Ahmed, HU.
(2009). BJC. High-intensity-focused ultrasound in the treatment
of primary prostate cancer: the first UK series, 101, 19-26.
2 Ahmed, HU. (2010).
Focal Therapy using HIFU (Sonablate 500) in Treating Localised
Low-Intermediate Risk Prostate Cancer. Poster presented at
the annual meeting of the American Urological Association,
San Fransisco, CA.
